ANAB Anaptysbio Inc
Price (delayed)
$18.4
Market cap
$564.27M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.12
Enterprise value
$457.23M
Imsidolimab, previously known as ANB019, is an antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, which AnaptysBio plans to initially develop as a potential first-in-class therapy for patients
Highlights
The company's gross profit has surged by 60% QoQ
ANAB's revenue has soared by 60% from the previous quarter
Anaptysbio's equity has decreased by 20% YoY and by 16% from the previous quarter
The company's quick ratio fell by 12% YoY and by 7% QoQ
Key stats
What are the main financial stats of ANAB
Market
Valuations
Earnings
Shares outstanding
30.67M
Market cap
$564.27M
Enterprise value
$457.23M
Price to earnings (P/E)
N/A
Price to book (P/B)
7.9
Price to sales (P/S)
5.72
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.01
Revenue
$91.28M
Gross profit
$91.28M
Operating income
-$114.95M
Net income
-$145.23M
EBIT
-$145.23M
EBITDA
-$142.83M
Free cash flow
-$135.7M
Per share
Balance sheet
Liquidity
EPS
-$5.12
EPS diluted
-$5.12
Free cash flow per share
-$4.78
Book value per share
$2.33
Revenue per share
$3.22
TBVPS
$17.05
Total assets
$483.83M
Total liabilities
$412.97M
Debt
$16.04M
Equity
$70.87M
Working capital
$386.45M
Debt to equity
0.23
Current ratio
9.51
Quick ratio
9.38
Net debt/EBITDA
0.75
Margins
Efficiency
Dividend
EBITDA margin
-156.5%
Gross margin
100%
Net margin
-159.1%
Operating margin
-125.9%
Return on assets
-32.1%
Return on equity
-272.9%
Return on invested capital
-45.6%
Return on capital employed
-33.1%
Return on sales
-159.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ANAB stock price
How has the Anaptysbio stock price performed over time
Intraday
-1.02%
1 week
-0.22%
1 month
9.39%
1 year
-13.7%
YTD
38.97%
QTD
-1.02%
Financial performance
How have Anaptysbio's revenue and profit performed over time
Revenue
$91.28M
Gross profit
$91.28M
Operating income
-$114.95M
Net income
-$145.23M
Gross margin
100%
Net margin
-159.1%
The company's operating margin has surged by 87% YoY and by 51% QoQ
ANAB's net margin has soared by 83% YoY and by 45% from the previous quarter
The company's gross profit has surged by 60% QoQ
ANAB's revenue has soared by 60% from the previous quarter
Growth
What is Anaptysbio's growth rate over time
Valuation
What is Anaptysbio stock price valuation
P/E
N/A
P/B
7.9
P/S
5.72
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.01
ANAB's EPS is up by 16% since the previous quarter and by 16% year-on-year
ANAB's P/B is 68% lower than its last 4 quarters average of 24.6 but 9% higher than its 5-year quarterly average of 7.3
Anaptysbio's equity has decreased by 20% YoY and by 16% from the previous quarter
The stock's price to sales (P/S) is 82% less than its 5-year quarterly average of 32.5 and 67% less than its last 4 quarters average of 17.5
ANAB's revenue has soared by 60% from the previous quarter
Efficiency
How efficient is Anaptysbio business performance
Anaptysbio's return on equity has shrunk by 129% YoY but it has increased by 5% QoQ
ANAB's return on sales has surged by 83% year-on-year and by 45% since the previous quarter
The return on invested capital has declined by 21% year-on-year but it has increased by 8% since the previous quarter
The ROA has increased by 14% QoQ
Dividends
What is ANAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ANAB.
Financial health
How did Anaptysbio financials performed over time
The total assets is 17% more than the total liabilities
The current ratio has declined by 13% year-on-year and by 7% since the previous quarter
The company's total liabilities rose by 13% YoY
ANAB's debt is 77% less than its equity
Anaptysbio's equity has decreased by 20% YoY and by 16% from the previous quarter
ANAB's debt to equity is up by 15% since the previous quarter and by 15% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.